NEW YORK, Jan. 13 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc. (BLU: TSX). The full 52-page report can be found at www.crystalra.com.
BELLUS Health Inc. ("BELLUS Health" or "the Company") is a global health company focused on providing innovative pharmaceutical and nutraceutical solutions for critical unmet needs. BELLUS Health aims to generate revenue in the short to medium term through the marketing and sale of branded nutraceutical products, thus enabling the medium- to long-term development and commercialization of its pharmaceutical pipeline. The Company's pharmaceutical products target disorders with no known cures and limited treatments. BELLUS Health's most advanced pharmaceutical candidate is KIACTA(TM) (eprodisate), a Phase III compound to treat Amyloid A (AA) amyloidosis, a disease marked by an accumulation of abnormal proteins that can lead to organ failure and death. In a Phase II/III trial of eprodisate, patients on KIACTA(TM) (eprodisate) had a lower risk of progression of AA amyloidosis-related renal disease and a slower rate of decline in creatinine clearance (a reduction in clearance indicates worsened renal disease). BELLUS Health expects to file a new protocol amendment to the Investigational New Drug (IND) application for the second pivotal Phase III clinical trial of KIACTA(TM) in the first quarter 2009.
The Company's other pharmaceutical developments include NC-503 (eprodisate), which is currently in a proof-of-concept Phase II study in patients with Type II diabetes and certain features of metabolic syndrome, and a prodrug program for Alzheimer's disease (AD), which is at the preclinical development stage. The Company, through its wholly owned subsidiary, OVOS Natural Health Inc., is also commercializing a condition-specific, clinically tested branded nutraceutical to protect memory. This first product, VIVIMIND(TM), was launched in Canada in September 2008 and is also available via the Internet. The Company plans to market VIVIMIND(TM) in the U.S. in 2009 and in the EU in 2011.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of fifty thousand U.S. dollars for its services in creating this report, for updates, and for printing costs.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed may constitute forward-looking statements as defined by applicable securities legislation. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC or SEDAR.
These statements and other forward-looking statements involve numerous risks and uncertainties, known and unknown. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
|SOURCE Crystal Research Associates, LLC|
Copyright©2009 PR Newswire.
All rights reserved